Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals

References

• Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. Lancet. 2016;388(10042):390–400.
   Google Scholar
• Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869–3903.
   Google Scholar
• Van Schuylenbergh J, Motmans J, Coene G. Transgender and non-binary persons and sexual risk: A critical review of 10 years of research from a feminist intersectional perspective. Crit Social Policy. 2018;38(1):121–142.
   Google Scholar
• Baral SD, Poteat T, Stromdahl S, et al. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013 Mar;13(3):214–222.
   Google Scholar
• Becasen JS, Denard CL, Mullins MM, et al. Estimating the prevalence of hiv and sexual behaviors among the us transgender population: A systematic review and meta-analysis, 2006-2017. Am J Public Health. 2018;29:e1–e8.
   Google Scholar
• Estimated HIV incidence and prevalence in the United States, 2010–2016: Centers for disease control and prevention; 2019 cited 2019 May 20. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
   Google Scholar
• Grov C, Westmoreland DA, Carrico AW, et al. Are we on the precipice of a new epidemic? Risk for hepatitis C among HIV-negative men-, trans women-, and trans men- who have sex with men in the United States. AIDS Care. 2020 May;32(sup2):74–82.
   Google Scholar
• Reisner SL, Vetters R, White JM, et al. Laboratory-confirmed HIV and sexually transmitted infection seropositivity and risk behavior among sexually active transgender patients at an adolescent and young adult urban community health center. AIDS Care. 2015;27(8):1031–1036.
   Google Scholar
• Wilson EC, Turner C, Lin J, et al. Hepatitis C seroprevalence and engagement in related care and treatment among trans women. J Viral Hepat. 2019 Jul;26(7):923–925.
   Google Scholar
• Poteat T UCSF transgender care & treatment guidelines: transgender health and hepatitis C 2016 updated 2016Jun17; cited 2020 May 21. Available from: https://transcare.ucsf.edu/guidelines/hepatitis-c
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2019 Dec 18.
   Google Scholar
• AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2020 Jan 20. Available from: http://www.hcvguidelines.org.
   Google Scholar
• Baecke C, Gyssens IC, Decoutere L, et al. Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study. Neth J Med. 2017 Jul;75(6):235–240.
   Google Scholar
• Jakeman B, Nasiri M, Ruth L, et al. Comparing the frequencies of contraindicated drug-drug interactions between differing antiretroviral regimens in HIV-infected patients. Ann Pharmacother. 2017 May;51(5):365–372.
   Google Scholar
• Patel N, Borg P, Haubrich R, et al. Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. Am J Health Syst Pharm. 2018 Aug 1;75(15):1132–1139.
   Google Scholar
• Ottman AA, Townsend ML, Hashem MG, et al. Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection. Ann Pharmacother. 2018 Aug;52(8):763–768.
   Google Scholar
• Braun HM, Candelario J, Hanlon CL, et al. Transgender women living with HIV frequently take antiretroviral therapy and/or feminizing hormone therapy differently than prescribed due to drug-drug interaction concerns. LGBT Health. 2017 Oct;4(5):371–375.
   Google Scholar
• Wiewel EW, Torian LV, Merchant P, et al. HIV diagnoses and care among transgender persons and comparison with men who have sex with men: New York City, 2006-2011. Am J Public Health. 2016 Mar;106(3):497–502.
   Google Scholar
• Jaspal R, Kennedy L, Tariq S. Human immunodeficiency virus and trans women: A literature review. Transgend Health. 2018;3(1):239–250.
   Google Scholar
• Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals. J Nerv Ment Dis. 2013 Nov;201(11):996–1000.
   Google Scholar
• Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgenderism. 2012;13(4):165–232.
   Google Scholar
• Yamazaki H, Shaw PM, Guengerich FP, et al. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol. 1998 Jun;11(6):659–665.
   Google Scholar
• Bicalutamide package insert: AstraZeneca pharmaceuticals LP; 2017 updated 2017Oct ; cited 2020 May 21. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
   Google Scholar
• Lupron injection” (leuprolide acetate) package insert: Abbvie inc; 2014 cited 2020 May 21. Available from: http://www.lupron.com/prescribing-information.aspx
   Google Scholar
• Zoladex package insert: Astrazeneca pharmaceuticals LP; 2015 updated 2015Feb ; cited 2020 May 21. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf
   Google Scholar
• Scarsi KK, Darin KM, Chappell CA, et al. Drug-drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV. Drug Saf. 2016 Nov;39(11):1053–1072.
   Google Scholar
• Chen H, Yang K, Choi S, et al. Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos. 2009 Sep;37(9):1841–1847.
   Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005 Aug;8(Suppl 1):3–63.
   Google Scholar
• ESTRACE product monograph: acerus pharmaceuticals corporation; 2015 cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00031946.PDF
   Google Scholar
• Lobo RA, Cassidenti DL. Pharmacokinetics of oral 17 beta-estradiol. J Reprod Med. 1992 Jan;37(1):77–84.
   Google Scholar
• Mattison DR, Karyakina N, Goodman M, et al. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps. Crit Rev Toxicol. 2014 Sep;44(8):696–724. .
   Google Scholar
• Williams JA, Ring BJ, Cantrell VE, et al. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos. 2002 Nov;30(11):1266–1273. .
   Google Scholar
• Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263–269.
   Google Scholar
• Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209–1212.
   Google Scholar
• Los LE, Pitzenberger SM, Ramjit HG, et al. Hepatic metabolism of spironolactone. production of 3-hydroxy-thiomethyl metabolites. Drug Metab Dispos. 1994 Nov-Dec;22(6):903–908.
   Google Scholar
• ALDACTAZIDE product monograph : pfizer Canada ULC; 2019 cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00050910.PDF
   Google Scholar
• ANDROCUR product monograph: bayer inc; 2011 cited 2019 Nov 29. Available from: https://pdf.hres.ca/dpd_pm/00012618.PDF
   Google Scholar
• Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284–1293.
   Google Scholar
• Wang H, Zhou L, Gupta A, et al. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E798–807.
   Google Scholar
• Drug development and drug interactions: table of substrates, inhibitors and inducers: U.S food and drug administration; 2019 updated 2019Dec03; cited 2020 Jan 20. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
   Google Scholar
• DEPO-TESTOSTERONE product monograph: pfizer Canada inc; 2018 updated 2018 Jul 12; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00046306.PDF
   Google Scholar
• Yano K, Seto S, Kamioka H, et al. Testosterone and androstenedione are endogenous substrates of P-glycoprotein. Biochem Biophys Res Commun. 2019 Nov 26;520(1):166–170.
   Google Scholar
• GENVOYA product monograph: bristol-myers squibb Canada; 2015 updated 2019Jul17; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00052276.PDF
   Google Scholar
• TIVICAY product monograph: viiv healthcare; 2020 updated 2020Jan 31; cited 2020 Feb 25. Available from: https://pdf.hres.ca/dpd_pm/00055026.PD
   Google Scholar
• ISENTRESS product monograph: merck Canada Inc; 2018 updated 2018 19 Sept; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00047442.PDF
   Google Scholar
• BIKTARVY product monograph: gilead sciences Canada; 2018 updated2019May 10 ; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00051423.PDF
   Google Scholar
• REYATAZ product monograph: bristol-myers squibb Canada Co; 2003 updated 2018Oct 26; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00048184.PDF
   Google Scholar
• KALETRA product monograph: abbvie corporation; 2001 updated 2019Sept27; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00053305.PDF
   Google Scholar
• PREZISTA product monograph janssen inc; 2006 updated 2019 Mar 28; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00050814.PDF
   Google Scholar
• NORVIR product monograph: abbvie corporation; 1996 updated Oct 20191; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00053358.PDF
   Google Scholar
• SUSTIVA product monograph: bristol-myers squibb Canada; 1999 cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00054291.PDF
   Google Scholar
• INTELENCE product monograph: janssen inc; 2008 updated2019Jun24; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00051875.PDF
   Google Scholar
• MYLAN-NEVIRAPINE product monograph: mylan pharmaceuticals ULC; 2014 cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00024016.PDF
   Google Scholar
• EDURANT product monograph: janssen inc; 2011 updated 2019 Mar 04; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00050300.PDF
   Google Scholar
• PIFELTRO Product Monograph: merck Canada Inc; 2018 updated 2019 Dec 05 ; cited 2020 Feb 26. Available from: https://pdf.hres.ca/dpd_pm/00054609.PDF
   Google Scholar
• Weiss J, Herzog M, Konig S, et al. Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242–250.
   Google Scholar
• Kakuda TN, Schöller-Gyüre M, Hoetelmans RMW. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs [journal article]. Clin Pharmacokinet. 2011;50(1):25–39.
   Google Scholar
• Begley R, Das M, Zhong L, et al. Pharmacokinetics of tenofovir alafenamide when coadministered with other hiv antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465–472.
   Google Scholar
• VOSEVI product monograph: gilead sciences inc; 2020 cited 2020 Feb 26. Available from: https://pdf.hres.ca/dpd_pm/00054818.PDF
   Google Scholar
• HARVONI product monograph: gilead sciences inc; 2020 updated 2020 Jan 31 ; cited 2020 Feb 26. Available from: https://pdf.hres.ca/dpd_pm/00054893.PDF
   Google Scholar
• ZEPATIER product monograph: merck Canada inc; 2016 updated 2017 Jun28; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00039964.PDF
   Google Scholar
• MAVIRET product monograph: abbvie corporation; 2019 updated 2019 Jun 25; cited 2019 Nov 28. Available from: https://pdf.hres.ca/dpd_pm/00051912.PDF
   Google Scholar
• Garrison KL, German P, Mogalian E, et al. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos. 2018 Aug;46(8):1212–1225.
   Google Scholar
• Leinung MC, Miller CH, Tehrani B, et al. The effect of efavirenz on estradiol metabolism in transgender women. Transgend Health. 2019;4(1):197–199.
   Google Scholar
• Scarsi KK, Cramer YS, Rosenkranz SL, et al. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Lancet HIV. 2019;6(9):e601–e612.
   Google Scholar
• Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16(2):149–156.
   Google Scholar
• Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. JAIDS Journal of Acquired Immune Deficiency Syndrome. 2010 Dec;55(4):473–482.
   Google Scholar
• Hiransuthikul A, Himmad L, Kerr SJ, et al. Drug-drug interactions among thai HIV-positive transgender women undergoing feminizing hormone therapy and antiretroviral therapy: the iFACT study. Clin Infect Dis. 2020 Jan 16; DOI:10.1093/cid/ciaa038.
   Google Scholar
• Hiransuthikul A, Janamnuaysook R, Himmad K, et al. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. J Int AIDS Soc. 2019 Jul;22(7):e25338.
   Google Scholar
• Cottrell ML, Prince HMA, Schauer AP, et al. Decreased tenofovir diphosphate concentrations in a transgender female cohort: implications for human immunodeficiency virus preexposure prophylaxis. Clin Infect Dis. 2019 Nov 27;69(12):2201–2204.
   Google Scholar
• Yager JL, Anderson PL .Pharmacology and drug interactions with HIV prEP in transgender persons receiving gender affirming hormone therapy. Expert Opin Drug Metab Toxicol. 2020:1–12. . doi:10.1080/17425255.2020.1752662.
   Google Scholar
• Shieh E, Marzinke MA, Fuchs EJ, et al. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc. 2019 Nov;22(11):e25405.
   Google Scholar
• Cirrincione LR, Podany AT, Havens JP, et al. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. J Antimicrob Chemother. 2020;75(5):1242–1249.
   Google Scholar
• Nanda K, Amaral E, Hays M, et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril. 2008 Oct;90(4):965–971.
   Google Scholar
• Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007 Feb;81(2):222–227.
   Google Scholar
• Luque AE, Cohn SE, Park J-G, et al. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015;59(4):2094–2101.
   Google Scholar
• Zia Y, Tang JH, Chinula L, et al. Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi. Contraception. 2019 Nov;100(5):402–405.
   Google Scholar
• Mngqibisa R, Kendall MA, Dooley K, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: potential concern for standard dosing frequency. Clin Infect Dis. 2019 Sep 5; DOI:10.1093/cid/ciz863.
   Google Scholar
• Kreutzwiser D, Tseng A. Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1211–1224.
   Google Scholar
• Lundahl A, Hedeland M, Bondesson U, et al. The effect of St. John’s wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci. 2009 Mar 2;36(4–5):433–443.
   Google Scholar
• Santos GM, Wilson EC, Rapues J, et al. HIV treatment cascade among transgender women in a San Francisco respondent driven sampling study. Sex Transm Infect. 2014 Aug;90(5):430–433.
   Google Scholar
• Magri A, Barbaglia MN, Foglia CZ, et al. 17,beta-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle. Liver Int. 2017 May;37(5):669–677.
   Google Scholar
• Wiepjes CM, de Blok CJ, Staphorsius AS, et al. Fracture risk in trans women and trans men using long-term gender-affirming hormonal treatment: a nationwide cohort study. J Bone Miner Res. 2020 Jan;35(1):64–70.
   Google Scholar
• Rothman MS, Iwamoto SJ. Bone health in the transgender population. Clin Rev Bone Miner Metab. 2019;17(2):77–85.
   Google Scholar
• Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017;102(11):3904–3913.
   Google Scholar
• Vlot MC, Wiepjes CM, de Jongh RT, et al. Gender-affirming hormone treatment decreases bone turnover in transwomen and older transmen. J Bone Miner Res. 2019 Oct;34(10):1862–1872.
   Google Scholar
• Stellbrink H-J, Lazzarin A, Woolley I, et al. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med. 2020;21(S1):3–16.
   Google Scholar
• Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688.
   Google Scholar
• Rosen HN,Hamnvik OPR, Jaisamrarn U, et al. Bone densitometry in transgender and gender non-conforming (TGNC) individuals: 2019 ISCD official position. J Clin Densitom 2019;22(4):544-553.
   Google Scholar
• Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018;169(4):205–213.
   Google Scholar
• Nota NM, Wiepjes CM, de Blok CJ, et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study. Circulation. 2019;139(11):1461–1462.
   Google Scholar
• Arnold JD, Sarkodie EP, Coleman ME, et al. Incidence of venous thromboembolism in transgender women receiving oral estradiol. J Sex Med. 2016 Nov 01;13(11):1773–1777.
   Google Scholar
• Llibre JM, Hill A. Abacavir and cardiovascular disease: a critical look at the data. Antiviral Res. 2016;132:116–121.
   Google Scholar
• Leach C, Bishop B. Pharmacotherapy considerations in the management of transgender patients: an alternative viewpoint. Pharmacotherapy. 2016 Apr;36(4):e28–9.
   Google Scholar
• Goldstein Z, Corneil TA, Greene DN. When gender identity doesn’t equal sex recorded at birth: the role of the laboratory in providing effective healthcare to the transgender community. Clin Chem. 2017;63(8):1342–1352.
   Google Scholar
• Bishop BM. Pharmacotherapy considerations in the management of transgender patients: a brief review. Pharmacotherapy. 2015 Dec;35(12):1130–1139.
   Google Scholar
• Humble RM, Imborek KL, Nisly N, et al. Common hormone therapies used to care for transgender patients influence laboratory results. J Appl Lab Med. 2019;3:799-814. DOI: 10.1373/jalm.2018.027078.
   Google Scholar
• Klaver M, Dekker M, de Mutsert R, et al. Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis. Andrologia. 2017 Jun;49(5):e12660.
   Google Scholar
• Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol (Lausanne). 2018;9:705.
   Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clinl Infect Dis. 2019; DOI:10.1093/cid/ciz999.
   Google Scholar
• Schafer JJ, Sassa KN, O’Connor JR, et al. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019 Oct 6;(10):ofz414. DOI:10.1093/ofid/ofz414
   Google Scholar
• Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016 Apr;17(4):255–268.
   Google Scholar
• European AIDS clinical society guidelines version 10.0: European AIDS clinical society; 2019 cited 2020 Feb 29. Available from: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf.
   Google Scholar
• Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020 Mar;16(3):177–189.
   Google Scholar
• Shipley LC, Steele DT, Wilcox CM, et al. A rare cause of acute pancreatitis in a transgender female. J Investig Med High Impact Case Rep. 2020 Jan 01;8:2324709620921333.
   Google Scholar
• Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. Jama. 2005;293(3):330–339.
   Google Scholar
• Henriksson P, Einarsson K, Eriksson A, et al. Estrogen-induced gallstone formation in males. relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J Clin Invest. 1989;84(3):811–816.
   Google Scholar
• Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14 cases. Clinl Infect Dis. 2012;55(9):1270–1272.
   Google Scholar
• Alvarellos M, Guillemette C, Altman RB, et al. PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2018;28(5):127–137. .
   Google Scholar
• Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacother J Human Pharmacol Drug Ther. 2004;24(12):1732–1747.
   Google Scholar
• Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2017 Nov 1;102(11):3914–3923.
   Google Scholar
• Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017 Aug 09;17(1):551.
   Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010 Jan 30;375(9712):396–407.
   Google Scholar
• Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010 Jul 17;24(11):1781–1784.
   Google Scholar
• Witcomb GL, Bouman WP, Claes L, et al. Levels of depression in transgender people and its predictors: results of a large matched control study with transgender people accessing clinical services. J Affect Disord. 2018 Aug 01;235:308–315.
   Google Scholar
• Heylens G, Verroken C, De Cock S, et al. Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J Sex Med. 2014;11(1):119–126.
   Google Scholar
• Fisher AD, Castellini G, Ristori J, et al. Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. J Clin Endocrinol Metab. 2016;101(11):4260–4269.
   Google Scholar
• Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014 Jul 1;161(1):1–10.
   Google Scholar
• Mollan KR, Tierney C, Hellwege JN, et al. Race/ethnicity and the pharmacogenetics of reported suicidality with efavirenz among clinical trials participants. J Infect Dis. 2017 Sep 1;216(5):554–564.
   Google Scholar
• Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. Aids. 2014;28(7):989–997.
   Google Scholar
• Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019 Feb 1;68(4):535–544.
   Google Scholar
• Carey D, Puls R, Amin J, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul;15(7):793–802.
   Google Scholar
• Barber M, Nguyen LS, Wassermann J, et al. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019;115(5):878–894.
   Google Scholar
• Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012 May 1;60(1):33–42.
   Google Scholar
• Abdelhady AM, Shugg T, Thong N, et al. Efavirenz inhibits the human ether-a-go-go related current (hERG) and induces QT interval prolongation in CYP2B6*6*6 allele carriers. J Cardiovasc Electrophysiol. 2016 Oct;27(10):1206–1213.
   Google Scholar
• Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase iii randomized trials. AIDS. 2013 Mar 27;27(6):939–950.
   Google Scholar
• Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010 Jan 2;24(1):55–65.
   Google Scholar
• Giguère P, Nhean S, Tseng AL, et al. Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications. Can J Cardiol. 2019 Mar 01;35(3):326–340.
   Google Scholar
• Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020;15(2):118–125.
   Google Scholar
• Webb AJ, McManus D, Rouse GE, et al. Implications for medication dosing for transgender patients: A review of the literature and recommendations for pharmacists. Am J Health Syst Pharm. 2020 Mar 5;77(6):427–433.
   Google Scholar
• Clinical pharmacology and biopharmaceutics review: glecaprevir (GLE), pibrentasvir (PIB): center for drug evaluation and research (CDER): U.S. food and drug administration; 2017 cited 2020 Mar 2. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000ClinPharmR.pdf
   Google Scholar
• Vosevi summary of product characteristics: gilead sciences UC; 2017 updated 2020Feb25 . [cited 2020 Feb 28]. Available from: https://www.ema.europa.eu/en/documents/product-information/vosevi-epar-product-information_en.pdf
   Google Scholar
• Hezode C, Kwo P, Sperl J, et al. Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy. Int J Womens Health 2019;11:617–628.
   Google Scholar
• PROMETRIUM (progesterone USP) capsules. Package Insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019781s017020843s011lbl.pdf Accessed Feb. 28, 2020.
   Google Scholar